What problem does this paper attempt to address?

This paper aims to solve the problem of poor efficacy of standard combined chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). Specifically, despite treatment with standard combined chemotherapy, the prognosis of patients with unresectable intrahepatic cholangiocarcinoma remains poor. Therefore, the researchers designed this phase II clinical trial to evaluate the efficacy and safety of radiotherapy combined with anti - PD - 1 antibody (camrelizumab) as a first - line treatment regimen in patients with unresectable intrahepatic cholangiocarcinoma without distant metastasis. ### Research Background - **Disease Characteristics**: Intrahepatic cholangiocarcinoma (iCCA) is the second most common liver malignancy, and its incidence and mortality have increased significantly in the past 10 - 20 years. Approximately 70% of patients are in locally advanced or metastatic disease at the time of initial diagnosis and are not eligible for surgical resection. - **Existing Treatments**: The standard first - line treatment is the combined chemotherapy of gemcitabine plus cisplatin, but the efficacy of this treatment regimen is limited. The median progression - free survival (PFS) is only 8.0 months, the median overall survival (OS) is 11.7 months, and the incidence of grade 3 or higher adverse events is as high as 70% or more. - **Immunotherapy**: Although immunotherapy has shown certain efficacy in some biliary tract cancer patients with high microsatellite instability (MSI) and mismatch repair deficiency, in most patients, the response rate of single - agent anti - PD - 1 treatment is usually less than 20%, and sometimes even less than 10%. ### Research Objectives - **Evaluate Efficacy**: Evaluate the anti - tumor activity of radiotherapy combined with camrelizumab as a first - line treatment regimen in patients with unresectable intrahepatic cholangiocarcinoma without distant metastasis. - **Evaluate Safety**: Evaluate the safety and tolerability of this combined treatment regimen. - **Explore Biomarkers**: Explore the correlation between tumor mutation burden (TMB), microsatellite instability (MSI) and PD - L1 expression and survival. ### Main Findings - **Primary Endpoint**: The 1 - year progression - free survival rate (PFS) is 44.4%. - **Secondary Endpoints**: - The objective response rate (ORR) is 61.1%. - The disease control rate (DCR) is 86.1%. - The median progression - free survival (PFS) is 12.0 months. - The median overall survival (OS) is 22.0 months. - **Safety**: 47.2% of patients experienced treatment - related adverse events (AE) of any grade, among which 13.9% of patients experienced grade 3 or higher adverse events. ### Conclusion The combination of radiotherapy and camrelizumab as a first - line treatment regimen shows good anti - tumor activity and a low level of toxicity in patients with unresectable intrahepatic cholangiocarcinoma without distant metastasis, and is worthy of further study.

Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report

Long Survival after Immunotherapy Plus Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

Effect of different PD‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma

A Metastatic Intrahepatic Cholangiocarcinoma Treated with Programmed Cell Death 1 Inhibitor: a Case Report and Literature Review

Integration of Radiotherapy with Anti-Pd-1 Antibody for the Treatment of Intrahepatic or Hilar Cholangiocarcinoma: Reflection from Four Cases

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy

Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy

Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy

Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study

Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma

Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma

105P A Phase II Study of SHR-1316 Plus IBI310 in Patients with Advanced Intrahepatic Cholangiocarcinoma after Failure of First-Line Therapy

First‐line Chemotherapy or in Combination with Programmed Cell Death Protein‐1 Antibody in Patients with Metastatic or Recurrent Biliary Tract Cancer

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma

Combining Radiation with Immune Checkpoint Inhibitors Therapy for HCC: from the Alteration of the Immune Microenvironment by Radiotherapy

Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemothera-py: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature